Trials / Completed
CompletedNCT05444569
A Study of LY3537021 in Healthy Participants
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Study to Evaluate the Safety and Tolerability of LY3537021 When Combined With GLP-1 Receptor Agonist in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 21 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to evaluate the safety and tolerability of LY3537021 when administered in combination with glucagon-like peptide (GLP-1) receptor agonist called liraglutide in treatment-naïve healthy participants. The study will include 2 parts. The study will last up to 16 and 22 weeks for part A and B, respectively which includes a screening period of 6 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3537021 | Administered SC. |
| DRUG | Liraglutide | Administered SC. |
| DRUG | Placebo | Administered SC. |
Timeline
- Start date
- 2022-08-08
- Primary completion
- 2023-02-24
- Completion
- 2023-02-24
- First posted
- 2022-07-06
- Last updated
- 2023-03-01
Locations
1 site across 1 country: Singapore
Source: ClinicalTrials.gov record NCT05444569. Inclusion in this directory is not an endorsement.